Equity - Swiss NS (CH) FUNDS - Swiss Excellence Class DPM CHF


October 31, 2024



FUND OBJECTIVE

NS (CH) FUNDS-Swiss Excellence is an open-end fund domiciled in Switzerland. The Fund's objective is to outperform the Swiss equity market measured by the "SLI" Swiss Leader Index® Total Return by investing mainly in Swiss shares. The manager integrates ESG criteria into the selection and weighting of companies in the portfolio.

HISTORICAL PERFORMANCE



MONTHLY PERFORMANCE (%) NET OF FEES

| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Fund | Index* |
|------|--------|--------|-------|--------|--------|--------|-------|--------|--------|--------|--------|--------|---------|---------|
| 2024 | 0.83% | 2.71% | 4.60% | -3.10% | 6.09% | -0.92% | 3.16% | 0.92% | -0.37% | -3.62% | | | 10.33% | 11.56% |
| 2023 | 7.42% | 0.83% | 1.19% | 2.19% | -1.74% | 0.87% | 0.30% | -1.95% | -2.33% | -5.57% | 6.44% | 3.04% | 10.43% | 11.76% |
| 2022 | -6.11% | -3.18% | 1.36% | -1.47% | -4.09% | -8.84% | 5.46% | -4.03% | -6.96% | 5.95% | 4.60% | -2.84% | -19.52% | -18.41% |
| 2021 | | | | | 3.80% | 3.64% | 2.19% | 1.82% | -5.97% | 3.93% | -0.34% | 5.25% | 14.75% | 16.07% |

STATISTICAL ANALYSIS (Since May 2021)

| Return | Fund Ind | dex* | Market Cap Breakdown |
|-------------------------------|----------|-------|--------------------------------------|
| Annualized return | 3.4% | 4.9% | _ |
| % Positive Months | 57% | 57% | Above CHF 50 bln 39.59 |
| Risk | Fund In | dex* | - |
| Annualized Volatility | 14.0% 1 | 4.0% | From CHF 10 bln to CHF 50 bln 38.725 |
| Sharpe Ratio (1%) | 0.17 | 0.28 | - |
| | | | From CHF 2 bin to CHF 10 bin 16.33% |
| Comparison To Benchmark | In | dex* | - |
| Annualized Alpha | - | 1.3% | From CHF 500 mln to CHF 2 bln 4.83% |
| Beta | | 0.99 | |
| Correlation | | 0.99 | 0% 10% 20% 30% 40% |
| Top Holdings | We | eight | Sector Breakdown |
| Roche Holding AG | 7 | .24% | |
| Novartis AG | 7 | .18% | Health Care 29.3% |
| Cie Financiere Richemont SA | 6 | .35% | Financials 22.5% |
| UBS Group AG | 5 | .40% | |
| Zurich Insurance Group AG | 5 | .10% | Industrials 18.0% |
| Holcim AG | 4 | .91% | Materials 11.5% |
| Nestle SA | 4 | .57% | Consumer Staples 7.4% |
| Swiss Re AG | 4 | .08% | |
| | 3 | .70% | Consumer Discretionary 6.4% |
| Lonza Group AG | 0 | | |
| Lonza Group AG Givaudan SA | | .21% | Information Technology 3.5% |

NS (CH) FUNDS - Swiss Excellence Class DPM CHF - Dividend

October 31, 2024

FUND COMMENTARY

Equity - Swiss

"Atomic" - Blondie, 1979

No less than 3 of the largest companies in the world (all part of the famous Mag-7) have announced their will to go "atomic", nuclear to be precise, to secure their ever-growing electricity needs in the future. Amazon, Alphabet and Microsoft made this bold move in the last few weeks, which marks a massive shift in the way nuclear energy is considered. This used to be the monopoly of Governments, directly or through their state-owned and/or regulated utilities, but the obvious enormous increase in electricity consumption related to data centres is pushing private companies to enter the power generation business. This, added to the space industry also being the subject of private initiatives, constitutes a serious change in domains that were, up to now, Government-led. What's next is anybody's guess, but there are chances that the very deep pockets of the Mag-7 and others will drive tectonic shifts in many industries. The US presidential race has some atomic characteristics as well, but more in the way both candidates behave, while the Q3 earnings season, which has started in October, was more muted than atomic, at least for the big market leaders. This has to be put in the context of rising long term yields (+50 and + 27 bps for the US and the German 10 year) and elevated valuations. There are no signs of an imminent severe slowdown for the US economy, and Europe's and China's difficult economic conditions aren't new. While credit behaved extremely well despite rising yields (+0.45% for the Itrax Crossover), equity markets were almost unanimously in the red: the MSCI World lost 2%, the S&P 500 1%, the Stoxx 600 3.4%, the MSCI Emerging Markets 4.4%, and the Chinese CSI300 3.2%. Japan was the sole outlier with a +1.9% return, but the Yen tumbled 6.3% versus the dollar. Oil zigged and zagged and ended the month up 1.6%, leaving again the spotlight to Gold, which added 4.1% and is up 33% year to date.

Swiss Excellence was down 3.62% (DPM class) in October versus -3.30% for the UCIT-compliant SLI Total Return index. On a year-to-date basis, the fund is up 9.18% versus +11.56% for the benchmark.

The fund underperformed its benchmark last month, all sectors were in negative territory. In relative terms, the fund's underweight in Sandoz and UBS combined with its overexposure to Cie Financiere Richemont, Swiss Re as well as its exposure to Landis+Gyr, Bossard and Huber+Suhner were the primary drivers of underperformance.

The largest contributors to the fund's performance were Sandoz (+11.6%), Accelleron Industries (+5.6%), Sonova (+3.8%), Holcim (+3.1%) and UBS (+1.8%). Conversely, the largest detractors included Straumann (-17.5%), Sika (-14.1%), Givaudan (-11.7%), Cie Financière Richemont (-6.3%), Partners Group (-6.1%) and Swiss Re (-5.2%). In October, the SMI, SLI, and SPI Extra recorded performances of -3.09%, -3.30%, and -3.96%, respectively.

We decided to divest our positions in Bucher, Daetwyler and Softwareone due to their performance significantly falling short of our expectations. However, we identified promising opportunities in Zurich Insurance, Alcon and UBS, and we reduced our exposure to Nestlé. Finally, we have initiated a new position in Comet, a CHF2.0 billion market cap leader in radio frequency power and X-ray technology. The company is well-placed in digitalisation and electrification. The semiconductor cycle showed recovery in 3Q24, and Comet's long-term growth outlook remains strong, driven by rising chip production demand and advancements like Al that require complex semiconductor components.

Swiss Excellence now has a median market capitalisation of CHF 17.9 bln, the largest position being Roche (7.2%) and the smallest Medacta (0.3%). The main overweight sector is industrials (18.0% of the portfolio versus 10.2% for the benchmark), and the main underweight is healthcare (29.1% versus 32.0%). 21% of the portfolio is made up of companies with a market capitalisation of less than CHF 10 bln and 5% of our investments have a market capitalisation of less than CHF 10 bln and 5% of our investments have a market capitalisation of less than CHF 2 bln. Our top 5 positions are Roche, Novartis, Cie Financière Richemont, UBS and Zurich Insurance. The Swiss Excellence strategy, i.e. the DGC Swiss Excellence fund and NS (CH) Funds Swiss Excellence fund, now totals CHF 124.2 million.

GENERAL INFORMATION

| Fund Inception Strat. AUM (CHF) | 14-May-2021 124'210'942 | Subscription Redemption | Daily (1 Business Days) Daily (1 Business Days) | Fund Domicile Inv. Manager | Switzerland NS Partners SA |
|------------------------------------|----------------------------|----------------------------|--|-------------------------------|-------------------------------|
| AUM (CHF) | 71'801'421 | Management | Fee 1.50% | Administrator | GERIFONDS SA |
| Share classes | USD EUR CHF GBP | Performance | Fee 10.00% | Auditor | PricewaterhouseCoopers SA |
| Investment Min | None | NAV | 110.37 | Custodian | Banque Cantonale Vaudoise |
| ISIN (DPM CHF) | CH1106275048 | Dividend | Distributed | | |
| Fund Type | Swiss Fund | | | | |

www.nspgroup.com

This document is a Marketing Monthly Factsheet. The information contained in this communication is confidential and is for the exclusive use of the original recipient(s). In addition, this document is not intended for any person who is a citizen or resident of any jurisdiction where the publication, distribution or use of the information contained herein would be subject to any restrictions or limitations. This communication is for informational purposes only and it is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. All market prices, data, and other information are not waranted as to their completeness or accuracy and are subject to change without notice. Past performances are not indicative or a guarantee of current or future returns. Performance figures are calculated on a NAV basis, taking into account dividends, if any, but no subscription or redemption fees that might be levied. Fund values rise as well as fall, and losses on investment may equal or exceed original investment. Any comments or statements made herein do not necessarily reflect those of NS Partners Europe SA, NS Partners SA or its subsidiaries and affiliates. Moreover every investor is recommended to seek legal and fiscal advice before taking any investment decision, and to ascertain that the contemplated investment is suitable in terms of his investment experience, knowledge and financial situation. For additional information, please refer to the prospectus and fund contract of the fund. The prospectus and fund contract the KID, the semi-annual and annual reports are available free of charge at GERIFONDS SA (www.gerifonds.ch), the fund management company. - SIX Index AG (hereafter: SIX) is the source of the index : Swiss Leader Index Total Return and the data comprised therein. SIX has not been involved in any way in the creation of any reported information and does not give any warranty and excludes any liability whatsoever (whether in negligen

